As a nonprofit that intends to provide experimental ASO medicines for free for life to nano-rare patients, n-Lorem has no intention of commercial development for its medicines.  As such, n-Lorem’s limited resources are earmarked for the costs associated with discovering, developing and manufacturing experimental ASO medicines.  Because of this, n-Lorem cannot pay institutions to cover the costs associated with providing data to allow assessment of the performance of the ASO medicine.